

Chang-Li Wang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7696018/chang-li-wang-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39 papers	504 citations	13 h-index	21 g-index
46 ext. papers	707 ext. citations	3.5 avg, IF	3.4 L-index

#	Paper	IF	Citations
39	miR-31-5p modulates cell progression in lung adenocarcinoma through TNS1/p53 axis.. <i>Strahlentherapie Und Onkologie</i> , 2022 , 198, 304	4.3	1
38	Identification of a DNA damage repair gene-related signature for lung squamous cell carcinoma prognosis.. <i>Thoracic Cancer</i> , 2022 ,	3.2	1
37	Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021 , 12, 1469-1488	3.2	3
36	Bevacizumab-Induced Mitochondrial Dysfunction, Endoplasmic Reticulum Stress, and ERK Inactivation Contribute to Cardiotoxicity. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 5548130	6.7	2
35	CITED4 enhances the metastatic potential of lung adenocarcinoma. <i>Thoracic Cancer</i> , 2021 , 12, 1291-1303	3.2	1
34	Urinary malate dehydrogenase 2 is a new biomarker for early detection of non-small-cell lung cancer. <i>Cancer Science</i> , 2021 , 112, 2349-2360	6.9	7
33	Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation. <i>Molecular Oncology</i> , 2021 , 15, 1130-1145	7.9	3
32	Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2021 , 12, 2698-2709	3.2	3
31	Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis. <i>EBioMedicine</i> , 2020 , 53, 102689	8.8	6
30	The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 918-927	3.2	5
29	LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR-mutant lung cancers. <i>Cancer Letters</i> , 2020 , 486, 58-70	9.9	25
28	Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 3234-3242	3.2	5
27	Sorting and gene mutation verification of circulating tumor cells of lung cancer with epidermal growth factor receptor peptide lipid magnetic spheres. <i>Thoracic Cancer</i> , 2020 , 11, 2887-2895	3.2	1
26	Tumor Differentiation and Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery. <i>Cancer Management and Research</i> , 2020 , 12, 12549-12556	3.6	1
25	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2235-2245	2.2	94
24	TTP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 1509-1519	4.9	2
23	Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 914-923	8.9	39

22	Alteration in gene expression profiles of thymoma: Genetic differences and potential novel targets. <i>Thoracic Cancer</i> , 2019 , 10, 1129-1135	3.2	6
21	Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition). <i>Translational Lung Cancer Research</i> , 2019 , 8, 1163-1173	4.4	9
20	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018 , 7, 428-436	4.4	5
19	Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stage IB-IIIA non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 8508-8508	2.2	1
18	Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 237-245	8.9	30
17	Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2935-2942	2.2	16
16	A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. <i>ESMO Open</i> , 2017 , 2, e000174	6	3
15	Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: role of epidermal growth factor receptor activation. <i>Oncotarget</i> , 2017 , 8, 23033-23047	3.3	13
14	Prognostic factors and combined histologies in 205 resected small cell lung cancer (SCLC) patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20009-e20009	2.2	
13	Claudin-1 correlates with poor prognosis in lung adenocarcinoma. <i>Thoracic Cancer</i> , 2016 , 7, 556-563	3.2	13
12	Validation of the Chinese version of EORTC QLQ-BM22 in patients with bone metastases. <i>Supportive Care in Cancer</i> , 2016 , 24, 1019-24	3.9	1
11	Osteopontin-expressing macrophages in non-small cell lung cancer predict survival. <i>Annals of Thoracic Surgery</i> , 2015 , 99, 1140-8	2.7	18
10	Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 15690-703	3.3	23
9	A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014 , 86, 207-12	5.9	30
8	Prognostic value of the lymph node ratio in stage III gastric cancer patients undergoing radical resection. <i>PLoS ONE</i> , 2014 , 9, e96455	3.7	17
7	Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. <i>Annals of Thoracic Surgery</i> , 2013 , 96, 1943-51	2.7	28
6	Survival study of neoadjuvant versus adjuvant chemotherapy with docetaxel combined carboplatin in resectable stage IB to IIIA non-small lung cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7537-7537	2.2	3
5	Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e19161-e19161	2.2	2

4	Osteopontin knockdown suppresses non-small cell lung cancer cell invasion and metastasis. <i>Chinese Medical Journal</i> , 2013 , 126, 1683-8	2.9	13
3	Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients. <i>World Journal of Surgery</i> , 2012 , 36, 455-62	3.3	37
2	The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis. <i>PLoS ONE</i> , 2012 , 7, e38046	3.7	33
1	The role of chemokine receptor CXCR7 in lung cancer. <i>Clinical Oncology and Cancer Research</i> , 2010 , 7, 342-346		